Local view for "https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/703"
| Predicate | Value (sorted: default) |
|---|---|
| rdfs:label | |
| rdf:type | |
| ?:Evidence_enzyme_system | |
| ?:Evidence_type | |
| ?:content |
"route of administration: oral
study duration: single dose
population: 6 males
ages: 23 - 42
NOTE: participants were not tested for known CYP phenotypes and this might have affected the results (e.g. see Section "radiocarbon excretion" on p. 83)
Quote:
Disposition and biotransformation of the new antipsychotic agent olanzapine (OLZ) were studied in six male healthy volunteers after a single oral dose of 12.5 mg containing 100 microCi of [14C]OLZ. Biological fluids were analyzed for total radioactivity, the parent compound (GC/MS), and metabolites (electrospray LC/MS and LC/MS/MS). Mean radiocarbon recovery was approximately 87%, with 30% appearing in the faces and 57% excreted in the urine."
|
| dc:creator | |
| dc:date |
"06/16/2009 18:16:40"
|
| rdfs:seeAlso |
All properties reside in the graph file:///home/swish/src/ClioPatria/guidelines/dikb.ttl
The resource appears as object in one triple:
{ olanzapine_primary_total_clearance_mechanism_Metabolic_Clearance, <http://purl.org/swan/1.2/swan-commons#citesAsSupportingEvidence>, evidence_1244 }